Navigation Links
Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting

-- Data from Picoplatin Phase 1 Colorectal and Prostate Cancer Trials To Be Published in 2007 ASCO Proceedings --

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell lung cancer (SCLC) will be presented in a poster session at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Details are as follows:

    -- Abstract #7722, Poster #EE3

       A Phase 2 study of picoplatin as second-line therapy for patients with

       small cell lung cancer who have resistant or refractory disease or have

       relapsed within 180 days of completing first-line, platinum-containing

       chemotherapy.

       Bentzion D, Lipatov O, Poliakov I, MacKintosh R, Eckardt J, Breitz H.

       General Poster Session: Sunday, June 3, 8:00 a.m. to 12 p.m. Central

       time S Hall A2

In addition, two picoplatin abstracts have been selected for publication in the 2007 ASCO Proceedings and will be available online through http://asco.org. These abstracts include safety data from an ongoing Phase 1/2 study of picoplatin for the potential front-line treatment of colorectal cancer and from an ongoing Phase 1/2 study of picoplatin and docetaxel (Taxotere(R)) in chemotherapy-naive patients with metastatic hormone-refractory prostate cancer. Details are as follows:

    -- Abstract #14510

       Phase 1 study of picoplatin in combination with 5-fluorouracil and

       leucovorin as initial therapy in subjects with metastatic colorectal

       cancer.

       Gladkov Jr O, Manikhas G, Biakhov M, Tjulandin S, Karlin D.


    -- Abstract #15546

       Phase 1 study of picoplatin and doc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... Nov. 10, 2010 SCOLR Pharma, Inc. (NYSE AMEX: ... and nine months ended September 30, 2010.Stephen J. Turner, SCOLR ... of the year will be to continue executing the plans ... which have both been advanced in the last quarter. ...
... Nov. 10, 2010 The Halifax Health - Betty ... celebrated the beginning of a new decade of caring ... during a ceremony held this afternoon in Daytona Beach, ... and Halifax Health will celebrate the 10th anniversary of ...
Cached Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 7Speediatrics Unit Celebrates 10th Anniversary 2Speediatrics Unit Celebrates 10th Anniversary 3
(Date:7/31/2014)... “Bivalent, Heteronomy and Natural Killer Cells?” opened ... bands ~ homeostatic CS science is the answer.” , ... new on the Bryan William Brickner Blog, ten ... cannabinoid system (CS). The line-up links to PubMed articles ... directly on homeostasis, two each on the central nervous, ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on nine secrets that addicts don’t ... that they can spot an addict from a mile away, ... best Drug Rehabilitation’s CEO Per Wickstrom . “However, take ...
(Date:7/31/2014)... 2014 Continuing Education Company Inc ... Clinical Issues in Primary Care Continuing Medical ... at the Wailea Beach Marriott Resort and Spa on ... been developed for today's Primary Care practitioners. In 5 ... says Barbara Lyons, VP Education. , The agenda for ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... DC (PRWEB) July 31, 2014 ... health care environment more responsive to an increasingly ... years of experience and scholarly expertise to the ... the health care professions: "Diversity and Cultural Competence ... 2013). Janice L. Dreachslin, PhD, a professor in ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Chase, MD Postmenopausal women who have higher testosterone levels ... resistance and the metabolic syndrome compared to women with ... for publication in The Endocrine Society,s Journal of ... is an important step, say researchers, in understanding the ...
... ... and Total Health the all-natural herbal Nutraceutical Company together for the health of our ... ... Association and Registry (ACTHA) announced today that Total Health Enhancement Corp. ...
... ... Scrubs& Beyond shipped directly to their home or work! , ... Brentwood, MO (PRWEB) November 4, 2009 -- Medical professionals ... to their home or work! Orders will ship via SmartPost, which is a collaboration between ...
... Due to the increasing complexities of treating digestive diseases, ... enhanced abilities and experiences in specific disease areas or ... to a "Report of the Multisociety Task Force on ... the achievements of trainees based on specific defined competencies ...
... Nov. 3 Robbins & Myers, Inc. (NYSE: RBN ... Annual Industrial Conference on November 11, 2009. Representing the ... Officer, and Christopher M. Hix, Vice President and Chief Financial ... from 8:20-8:50 a.m., CT, at the Four Seasons Hotel in ...
... of Hematology (ASH) is honoring two prominent hematologists with ASH ... in the training and career development of hematologists early in ... MD, will receive their awards during the 51st ASH Annual ... receiving the Mentor Award for Basic Science, is the David ...
Cached Medicine News:Health News:Postmenopausal women with higher testosterone levels 2Health News:American Competitive Trail Horse Association Announces Total Health Enhancement Corp. as a Sponsor Member 2Health News:Smart Post Brings Scrubs & Beyond to Canadian Doorsteps 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 3Health News:The American Society of Hematology to honor inspirational hematologists with Mentor Awards 2